Tandem Diabetes Q3 sales rise 2%, gross margin improves

Tandem Diabetes Care

06/11/2025 22:03

Overview

Tandem Q3 2025 sales rose to $249.3 mln, achieving record quarterly sales

Adjusted net loss was slightly more than analysts' expectations

Gross margin improved to 54% from 51% year-over-year

Company reaffirmed full-year 2025 guidance, estimating $1.0 bln in sales

Outlook

Company reaffirms 2025 sales guidance at approximately $1.0 bln

Tandem expects 2025 U.S. sales of about $700 mln

Company anticipates 2025 gross margin of 53% to 54%

Result Drivers

RECORD SALES - Achieved record quarterly sales in both U.S. and international markets

STRATEGIC INITIATIVES - Progressed multi-channel initiative including increased pharmacy benefit coverage and product clearances

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted Net Income
Slight Miss*
-$21.20 mln
-$21.10 mln (16 Analysts)
Q3 Net Income
-$21.20 mln
Q3 Gross Margin
54.00%
Q3 Adjusted Operating income
Miss
-$22.90 mln
-$22.40 mln (15 Analysts)
Q3 Operating income
-$22.90 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 15 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Tandem Diabetes Care Inc is $15.50, about 5.4% above its November 5 closing price of $14.67

Press Release: ID:nBwbB33tZa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)